@article{5d8dcaa489da4d788c3c1bc46fe280cd,
title = "Loss of Cntnap2 Causes Axonal Excitability Deficits, Developmental Delay in Cortical Myelination, and Abnormal Stereotyped Motor Behavior",
abstract = "Contactin-associated protein-like 2 (Caspr2) is found at the nodes of Ranvier and has been associated with physiological properties of white matter conductivity. Genetic variation in CNTNAP2, the gene encoding Caspr2, has been linked to several neurodevelopmental conditions, yet pathophysiological effects of CNTNAP2 mutations on axonal physiology and brain myelination are unknown. Here, we have investigated mouse mutants for Cntnap2 and found profound deficiencies in the clustering of Kv1-family potassium channels in the juxtaparanodes of brain myelinated axons. These deficits are associated with a change in the waveform of axonal action potentials and increases in postsynaptic excitatory responses. We also observed that the normal process of myelination is delayed in Cntnap2 mutant mice. This later phenotype is a likely modulator of the developmental expressivity of the stereotyped motor behaviors that characterize Cntnap2 mutant mice. Altogether, our results reveal a mechanism linked to white matter conductivity through which mutation of CNTNAP2 may affect neurodevelopmental outcomes.",
keywords = "myelin, GABAergic interneurons, axonal action potentials, Kv1-family potassium channels, Caspr2",
author = "Ricardo Scott and Alberto S{\'a}nchez-Aguilera and {van Elst}, Kim and Lynette Lim and Nathalie Dehorter and Bae, {Sung Eun} and Giorgia Bartolini and Elior Peles and Kas, {Martien J H} and Hilgo Bruining and Oscar Mar{\'i}n",
note = "Funding Information: This work was supported by grants from the Spanish Ministerio de Econom{\'i}a y Competitividad (SAF2010-20604) to R.S.; Israel Science Foundation to E.P.; Simons Foundation (SFARI 239766) to E.P. and O.M.; European Research Council (ERC-2011-AdG 293683) to O.M.; and European Autism Interventions – A Multicentre Study for Developing New Medications (EU-AIMS) to M.K. EU-AIMS is a project receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115 300, resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013), from the EFPIA companies in kind contribution, and from Autism Speaks. O.M. is a Wellcome Trust Investigator. Funding Information: This work was supported by grants from the Spanish Ministerio de Econom{\'i}a y Competitividad (SAF2010-20604) to R.S.; Israel Science Foundation to E.P.; Simons Foundation (SFARI 239766) to E.P. and O.M.; European Research Council (ERC-2011-AdG 293683) to O.M.; and European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) to M.K. EU-AIMS is a project receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115 300, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), from the EFPIA companies in kind contribution, and from Autism Speaks. O.M. is a Wellcome Trust Investigator. Publisher Copyright: {\textcopyright} The Author(s) 2017.",
year = "2019",
month = feb,
doi = "10.1093/cercor/bhx341",
language = "English",
volume = "29",
pages = "586--597",
journal = "Cerebral Cortex",
issn = "1047-3211",
publisher = "Oxford University Press",
number = "2",
}